Pancreatic Cancer
Conditions
Brief summary
Pancreatic ductal adenocarcinoma (PDAC) is largely heterogeneous. We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC. Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3K/AKT/mTOR pathway markers were examined in consecutive patients with PDAC. A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model, and validated in two independent cohorts.
Interventions
DRUGChemotherapy
All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* ECOG performance status score of 0-1 before resection * complete clinicopathologic and follow-up data * availability of formalin-fixed paraffin-embedded (FFPE) specimens of resected primary tumor and hematoxylin and eosin slides with invasive tumor components
Exclusion criteria
* any previous history of cancer * any anticancer therapy prior to resection or adjuvant radiotherapy * metastatic cases * major postsurgical complications with Clavien-Dindo Grade ≥2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 3-year | Time between resection and death of any cause |
Countries
China
Outcome results
None listed